Discontinued — last reported Q3 '23
Trane Technologies Long-Term Debt - Fair Value increased by 2.2% to $4.60B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 13.2%, from $5.30B to $4.60B. Over 4 years (FY 2020 to FY 2024), Long-Term Debt - Fair Value shows a downward trend with a -7.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.90B | $5.70B | $5.60B | $5.10B | $4.70B | $4.50B | $4.60B | $4.70B | $4.90B | $4.50B | $4.70B | $4.80B | $5.10B | $5.30B | $4.60B | $4.70B | $4.50B | $4.60B |
| QoQ Change | — | -3.4% | -1.8% | -8.9% | -7.8% | -4.3% | +2.2% | +2.2% | +4.3% | -8.2% | +4.4% | +2.1% | +6.3% | +3.9% | -13.2% | +2.2% | -4.3% | +2.2% |
| YoY Change | — | — | — | — | -20.3% | -21.1% | -17.9% | -7.8% | +4.3% | +0.0% | +2.2% | +2.1% | +4.1% | +17.8% | -2.1% | -2.1% | -11.8% | -13.2% |